Abstract
Cytokines and chemokines play a very important role in a number of inflammatory diseases. In activated T cells, transcription factors such as the activator protein-1 (AP-1) regulate IL-2 production and production of matrix metalloproteinases, the nuclear factor kappa B (NF-κB) is essential for the transcriptional regulation of the proinflammatory cytokines IL-1, IL-6, IL-8 and TNFα, and nuclear factor of activated T-cells (NFAT) is required for the transcriptional regulation of IL-2, IL-3, IL-4, IL-5, IL-8, IL-13, TNFα, and GM-CSF. During the last few years, several groups have developed inhibitors of AP-1, NF-κB or both, and NFAT. This review article presents the recent progress in the development of inhibitors for AP-1, NF-κB, and NFAT mediated transcriptional activation.
Keywords: Inhibitors, AP-1, NF-B, Transcriptional Activation, Autoimmune Diseases, Cytokines, chemokines, AP-1 PATHWAY, NF-kB PATHWAY, Erythromycin
Current Medicinal Chemistry
Title: Inhibitors of AP-1 and NF-κB Mediated Transcriptional Activation: Therapeutic Potential in Autoimmune Diseases and Structural Diversity
Volume: 9 Issue: 2
Author(s): Moorthy s.s. Palanki
Affiliation:
Keywords: Inhibitors, AP-1, NF-B, Transcriptional Activation, Autoimmune Diseases, Cytokines, chemokines, AP-1 PATHWAY, NF-kB PATHWAY, Erythromycin
Abstract: Cytokines and chemokines play a very important role in a number of inflammatory diseases. In activated T cells, transcription factors such as the activator protein-1 (AP-1) regulate IL-2 production and production of matrix metalloproteinases, the nuclear factor kappa B (NF-κB) is essential for the transcriptional regulation of the proinflammatory cytokines IL-1, IL-6, IL-8 and TNFα, and nuclear factor of activated T-cells (NFAT) is required for the transcriptional regulation of IL-2, IL-3, IL-4, IL-5, IL-8, IL-13, TNFα, and GM-CSF. During the last few years, several groups have developed inhibitors of AP-1, NF-κB or both, and NFAT. This review article presents the recent progress in the development of inhibitors for AP-1, NF-κB, and NFAT mediated transcriptional activation.
Export Options
About this article
Cite this article as:
Palanki s.s. Moorthy, Inhibitors of AP-1 and NF-κB Mediated Transcriptional Activation: Therapeutic Potential in Autoimmune Diseases and Structural Diversity, Current Medicinal Chemistry 2002; 9 (2) . https://dx.doi.org/10.2174/0929867023371265
DOI https://dx.doi.org/10.2174/0929867023371265 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vitiligo in Children: A Birds Eye View
Current Pediatric Reviews Treatment of Refractory Autoimmune Diseases with Ablative Immunotherapy Using Monoclonal Antibodies and / or High Dose Chemotherapy with Hematopoietic Stem Cell Support
Current Pharmaceutical Design Migraine in Systemic Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Osteopontin; as a Target Molecule for the Treatment of Inflammatory Diseases
Current Drug Targets Glucocorticoids Pharmacology: Past, Present and Future
Current Pharmaceutical Design Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Medical and Societal Impact
Current Immunology Reviews (Discontinued) Inhibitors of Membrane Receptors Involved with Leukocyte Extravasation
Mini-Reviews in Medicinal Chemistry Novel Superactive Leptin Antagonists and their Potential Therapeutic Applications
Current Pharmaceutical Design Reactive Oxygen Species in the Initiation of IL-4 Driven Autoimmunity as a Potential Therapeutic Target
Current Pharmaceutical Design Functional Genome and Proteome Analyses of Cutaneous Autoimmune Diseases
Current Pharmaceutical Design Genetic and Pharmacological Modulation of Dendritic Cell-T Cell Interactions as a Therapeutic Strategy for Systemic Lupus Erythematosus
Current Gene Therapy Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target
Current Medicinal Chemistry Cannabinoids, Immune System and Cytokine Network
Current Pharmaceutical Design Tumor Necrosis Factor Inhibitors from Poxviruses with An Emphasis on Tanapoxvirus-2L Protein
Recent Patents on DNA & Gene Sequences Emerging Treatment Strategies and Potential Therapeutic Targets in Primary Sjogrens Syndrome
Inflammation & Allergy - Drug Targets (Discontinued) Vitamin D: Evolutionary, Physiological and Health Perspectives
Current Drug Targets Combinatorial Application of Multiple High-throughput Biotechnologies for the Study of Autoimmune Diseases
Current Pharmaceutical Analysis Immunomodulatory Role of Arsenic in Regulatory T Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Impact and Therapeutic Potential of PPARs in Alzheimers Disease
Current Neuropharmacology Mast Cells as Target in Cancer Therapy
Current Pharmaceutical Design